^
Association details:
| Biomarker: | AKT1 mutation + ER negative |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Truqap (capivasertib) (AKT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
Published date:
09/10/2020
Excerpt:
Participants were women (aged ≥18 years) with histologically confirmed advanced breast cancer...cohort D comprised patients with AKT1 mutations and oestrogen receptor-negative cancer or PTEN mutation (treated with oral capivasertib 480 mg)...Two (33%, 95% CI 4–78) of the six patients with AKT1 mutations responded, and there were two further unconfirmed responses in these patients.
DOI:
10.1016/S1470-2045(20)30444-7
Trial ID:
Test:
